Table 1.
Baseline patient characteristics
| Variable | DC vaccine + placebo (n = 5) | DC vaccine + poly-ICLC (n = 9) | DC vaccine + resiquimod (n = 9) | Total (n = 23) |
|---|---|---|---|---|
| Age (year) | ||||
| Mean (SD) | 56.50 (13.75) | 44.09 (12.04) | 43.73 (8.80) | 46.65 (11.98) |
| Median (IQR) | 48.06 (45.7-71.45) | 40.15 (35.35-54.6) | 43.46 (35.55-51.55) | 45.33 (37.4-72.8) |
| Sex | ||||
| Female, n (%) | 2 (40%) | 5 (56%) | 3 (33%) | 10 (43%) |
| Male, n (%) | 3 (60%) | 4 (44%) | 6 (67%) | 13 (57%) |
| OS (months) | ||||
| Median (IQR) | 7.7 (7.33-NA) | 52.5 (26.6-NA) | 16.7 (15.33-NA) | 24.5 (15.3-61.2) |
| TTP (months) | ||||
| Median (IQR) | 5.13 (4.5-NA) | 31.43 (13.4-NA) | 8.1 (6.2-NA) | 8.1 (6.13-31.3) |
| WHO grade, n (%) | ||||
| III | 1 (20%) | 4 (44%) | 3 (33%) | 7 (30%) |
| IV | 4 (80%) | 5 (56%) | 6 (67%) | 16 (70%) |
| Recurrence, n (%) | ||||
| None | 1 (20%) | 5 (56%) | 3 (33%) | 9 (39%) |
| Recurrence | 4 (80%) | 4 (44%) | 6 (67%) | 14 (61%) |
| MGMT status, n (%) | ||||
| Methylated | 1 (20%) | 4 (44%) | 3 (33%) | 8 (35%) |
| Unmethylated | 4 (80%) | 5 (56%) | 6 (67%) | 15 (65%) |
| EGFR classification, n (%) | ||||
| Amplified | 3 (60%) | 2 (22%) | 5 (56%) | 10 (44%) |
| Not amplified | 1 (20%) | 5 (56%) | 3 (33%) | 9 (39%) |
| Unknown | 1 (20%) | 2 (22%) | 1 (11%) | 4 (17%) |
| IDH status, n (%) | ||||
| Mutant | 1 (20%) | 4 (44%) | 3 (33%) | 8 (35%) |
| Wild-type | 4 (80%) | 5 (56%) | 6 (67%) | 15 (65%) |
| Avastin treatment, n (%) | ||||
| Treated | 4 (80%) | 5 (56%) | 6 (67%) | 15 (65%) |
| Not treated | 1 (20%) | 4 (44%) | 3 (33%) | 8 (35%) |